RARE Stock Overview
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ultragenyx Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$56.12 |
| 52 Week High | US$58.73 |
| 52 Week Low | US$31.52 |
| Beta | 0.57 |
| 11 Month Change | 14.34% |
| 3 Month Change | 34.35% |
| 1 Year Change | 44.68% |
| 33 Year Change | -45.14% |
| 5 Year Change | 24.68% |
| Change since IPO | 32.83% |
Recent News & Updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Recent updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers
Oct 13Ultragenyx grants stock options, restricted stock units
Oct 05Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue
Sep 02Shareholder Returns
| RARE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.9% | -2.1% | -1.9% |
| 1Y | 44.7% | 13.4% | 20.9% |
Return vs Industry: RARE exceeded the US Biotechs industry which returned 13.4% over the past year.
Return vs Market: RARE exceeded the US Market which returned 20.9% over the past year.
Price Volatility
| RARE volatility | |
|---|---|
| RARE Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RARE's share price has been volatile over the past 3 months.
Volatility Over Time: RARE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,276 | Emil Kakkis | www.ultragenyx.com |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. Fundamentals Summary
| RARE fundamental statistics | |
|---|---|
| Market cap | US$5.13b |
| Earnings (TTM) | -US$585.12m |
| Revenue (TTM) | US$481.30m |
10.7x
P/S Ratio-8.8x
P/E RatioIs RARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RARE income statement (TTM) | |
|---|---|
| Revenue | US$481.30m |
| Cost of Revenue | US$719.64m |
| Gross Profit | -US$238.34m |
| Other Expenses | US$346.78m |
| Earnings | -US$585.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.35 |
| Gross Margin | -49.52% |
| Net Profit Margin | -121.57% |
| Debt/Equity Ratio | 205.6% |
How did RARE perform over the long term?
See historical performance and comparison